ZymoGenetics said it received Food and Drug Administration approval Thursday to market its first commercial product, which helps control...
ZymoGenetics said it received Food and Drug Administration approval Thursday to market its first commercial product, which helps control bleeding during surgery.
The regulatory OK also triggers a $40 million milestone payment from Bayer, its partner in marketing the product, which it calls Recothrom. Seattle-based Zymo hopes the product, previously known as rThrombin, will surpass sales of competing products derived from animal or human blood, which the company says are more risky.
Approval was originally expected in October, but the FDA asked for more information about the company’s manufacturing procedures.
ZymoGenetics shares were up $2.44, or 20 percent, to $14.44 in mid-day trading.
Most Read Business Stories
- 55,000 in Washington state may have to pay back thousands in jobless benefits
- 1 house, 45 offers: Homebuyers in Western Washington hard-pressed as supply remains scarce
- Boeing CEO gave up millions in pay; here's what he and other top execs earned
- Amazon's telehealth arm quietly expands to 21 more states
- Inflation isn't the big risk, with economy's recovery still uncertain